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Oxidative stressAbstract Aims: The aim of this study was to investigate the antioxidant effects of L-carnitine on
the oxidative stress parameters in oophorectomized rats.
Methods: Twenty-four female albino Wistar rats were used. Rats were divided into four groups:
laparotomy-only (LOSALINE) group, oophorectomy plus L-carnitine 100 mg/kg/day (OXL100)
group, oophorectomy plus L-carnitine 500 mg/kg/day (OXL500) group, and oophorectomy-only
(OXSALINE) group. Experimental protocol was started on day 21 post-castration. Various dosage
forms of L-carnitine or isotonic saline were administered intraperitoneally for 14 consecutive days.
Nitric oxide (NO), malondialdehyde (MDA), total antioxidant status (TAS), total oxidative stress
(TOS) and oxidative stress index (OSI) were evaluated in the tissues including kidney, liver and
heart, and sera.
Result(s): In the heart tissue samples, there was no difference in the levels of NO, OSI and TOS
between the groups. However, MDA levels in OXSALINE group were significantly higher than
OXL500 group. On the other hand, there was no statistically significant differences between the
groups in terms of levels of NO, MDA, TAS, TOS and OSI in liver, kidney and sera samples.
Conclusion(s): Levels of MDA in the heart tissue were significantly higher in OXSALINE group
compared to OXL500 group. Thus, it may be suggested that L-carnitine reduces oxidative stress at
least in the heart of oophorectomized rats.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Menopause is defined as the permanent cessation of menstru-
ation resulting from the loss of ovarian follicular activity. A
variety of physiological changes occur in the body; some of
56 E.P. Canbolat et al.them are related to cessation of ovarian functions, and others
are because of the aging process.1 It is also known that level of
lipid peroxide, a marker of free-radical production and cell
membrane lipid peroxidation (LPO), increases after
menopause.2 In various studies, it has been shown that the
menopause impairs oxidative systems and causes increase in
LPO.2,3 LPO is a process mediated by free oxygen radicals.
During this process, the polyunsaturated fatty acids that are
the structure of phospholipid, glycolipid, glyceride or sterol
present in cell membrane are converted into various noxious
products such as peroxides, alcohols, aldehydes, and hydroxy
fatty acids. One of the major end products of lipid peroxida-
tion, is malondialdehyde (MDA).4
Oxygen-free radicals more generally are known as reactive
oxygen species (ROS) along with reactive nitrogen species
(RNS), and one of them is also nitric oxide.4 Harmful effects
of oxidative stress are counteracted by the action of antioxi-
dants. It is well known that various estrogens scavenge reactive
oxygen species (ROS) efficiently in both aqueous and lipophilic
cellular components.5
Furthermore, many in vitro and animal studies have
reported that L-carnitine is a free radical scavenger, which pro-
tects antioxidant enzymes from oxidative damage.6 L-carnitine
is a quaternary amine containing seven carbon atoms with a
molecular mass of 161.2 g/mol, water-soluble, small, highly
polar compound which is widely distributed in nature.7
Carnitine exists in two isomeric forms: L-carnitine and D-
carnitine. Only the L-isomer of carnitine is metabolically active
and synthesized primarily in liver also in the kidney. Tissues
containing high levels of L-carnitine are unable to synthesize
it. Tissues, other than liver and kidney, are dependent on the
active uptake of carnitine from blood into tissues.8,9 It has
been reported that L-carnitine is a powerful antioxidant, and
L-carnitine exerts its antioxidant effect by preventing LPO.10–12
In this study, we aimed at investigating the protective
effects of L-carnitine against oxidative stress in various tissues
at the surgically menopausal rats.
2. Material and method
This study was conducted in the Experimental Medical
Research Unit (DETAB, Kırıkkale University Medical
Faculty, Kırıkkale, Turkey). The study protocol was approved
by Kırıkkale University Animal Research Ethical Committee
on 22.08.2011 (Approval Number 11/8-11-210).
2.1. Animals
A total of 24 adult female Wistar albino rats weighing 200–
250 g were used in the study. The rats were given ad libitum
access to a standard rat chow and tap water, and were housed
as a group per cage under standard controlled temperature
(20–22 C), humidity (40–60%), and light (12 h light/12 h
dark) in a facility for each group. All animal procedures com-
piled with the items of Helsinki Final Act (1986) related to
experimental animals.
2.2. Study protocol
The rats were randomly allocated to 4 groups: laparotomy-
only group (LOSALINE group; n= 6), oophorectomized-onlygroup (OXSALINE group; n= 6), oophorectomy plus 100 mg/
kg/day L-carnitine group (OXL100 group; n= 6) and
oophorectomy plus 500 mg/kg/day L-carnitine group (OXL500
group; n= 6). The rats were anaesthetized with intraperi-
toneal injections of ketamine 80 mg/kg (Ketalar, 50 mg/ml
vial; Pfizer Pharmaceuticals, Istanbul, Turkey) and 10 mg/kg
xylazine (Rompun, 100 mg/ml vial; Bayer, Leverkusen,
Germany) cocktail. All the interventions were performed
under aseptic conditions and the rats were spontaneously
breathing during surgical procedure. Surgery on each animal
was performed through a ventral midline incision. No inter-
vention other than incision was done in the SL group. The
ovaries were exposed and bilateral oophorectomy was per-
formed in the other three groups. Abdominal layers were
closed anatomically, using 4/0 atravmatic Vicryl and the ani-
mals were allowed to recover from anesthesia.
Experimental protocol was started on day 21 post-
castration. In rats, antioxidant dosage recommendations for
L-carnitine were 100 mg/kg13,14 and 500 mg/kg15,16 in the
literature.
LOSALINE group was administered 0.12 ml/day of isotonic
saline solution, OXL100 group was administered 100 mg/kg/-
day of L-carnitine, OXL500 group was administered 500 mg/
kg/day of L-carnitine and OXSALINE group was administered
0.12 ml/day of isotonic saline solution, intraperitoneally, for
14 consecutive days. On day 35 post-castration, all the animals
were anesthetized again and blood samples were obtained via
intra-cardiac puncture before the animals were sacrificed.
The blood samples were centrifuged at 10.000 rotations per
minute (rpm), at +4 C for 10 min (Eppendorf; 5804/R,
Germany). Sera obtained from blood samples were transferred
to polyethylene tubes. After removal the liver, heart and kid-
ney tissue samples were immediately washed with cooled iso-
tonic saline and placed on ice-cold plate. Sera and tissue
samples (liver, heart and kidney) were stored at 80 C until
they were used for analysis of nitric oxide (NO), malondialde-
hyde (MDA), total antioxidant status (TAS), and total oxida-
tive stress (TOS).
Flowchart of the study is presented in Fig. 1.2.2.1. MDA measurement
The evaluation of MDA was based on the modified version of
Yagi’s fluorometric method.17 MDA levels were calculated
using a standard curve and values are expressed as nmol/g
protein.
2.2.2. NO measurement
Nitrates/nitrites were assayed according to the method of
Miranda et al.18 NO (nitrates/nitrites) levels were calculated
using a standard curve and multiplying by the dilution factor.
Values are expressed as lmol/g protein.
2.2.3. TOS measurement
Erel’s method was used for measuring TOS.19 TOS was
assayed with TOS commercial kit (Rel Assay Diagnostics,
Gaziantep, Turkey, 2010) adapted to an Olympus AU 480
autoanalyzer (Fully Automatic Chemistry Analyser [AU480]
Olympus Diagnostics, Japan). The results are expressed as
micromolar hydrogen peroxide equivalents per g protein (lmol
H2O2 equiv/g protein).
Figure 2 MDA levels in heart tissues in all groups.
Figure 1 Flowchart of the study.
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Erel’s method was used for measuring TAS.20 TAS was
assayed with TAS commercial kit (Rel Assay Diagnostics,
Gaziantep, Turkey, 2010) adapted to an Olympus AU 480
autoanalyzer (Fully Automatic Chemistry Analyser [AU480]
Olympus Diagnostics, Japan). The results are expressed as
micromolar Trolox equivalents per g protein (lmol Trolox
equiv/g protein).
2.2.5. Calculation of oxidative stress index (OSI)
For calculation, the resulting unit of TAS was converted to
lmol/L, and the OSI value was calculated according to the fol-
lowing formula: OSI (arbitrary unit) = 100 * TOS (lmol
H2O2 equivalent/L)/TAS (lmol Trolox equiv/L).
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3. Statistical analysis
The Statistical Package for Social Sciences (SPSS) 11.5 for
Windows software (SPSS Inc., Chicago, IL, United States)
was used for statistical analysis. We used the Shapiro Wilk test
to test variables for normality of distribution. Levene’s testwas used for testing homogeneity of variances. Results of
descriptive analysis were presented as mean (±standard devi-
ation) or median (minimum–maximum). The parametric data
were statistically analyzed by one-way ANOVA and the inter
group comparison of means was conducted using a post hoc
Tukey’s HSD (Honestly Significant Difference) test. The non-
parametric data were analyzed by Kruskal-Wallis rank sum
tests followed by Conover’s multiple comparison tests. Results
are considered significant when p< 0.05.
4. Results
In the kidney tissue samples, levels of NO, MDA, and TOS in
OXSALINE group were higher (but not significantly) than those
in OXL100 and OXL500 groups (p> 0.05 for all comparisons).
There was no difference in TAS, and OSI levels of the groups
(p> 0.05 for all comparisons) (Table 1).
In the heart tissue samples, there was no difference in the
levels of NO, OSI and TOS between the groups (p> 0.05
for all comparisons). MDA levels in OXL500 group were signif-
icantly lower than those in OXSALINE group (p= 0.002)
(Table 2, Fig. 2).
In the liver tissue samples, there was no difference in the
levels of NO, MDA, TAS, TOS and OSI between the groups
(p> 0.05 for all comparisons) (Table 3).
In the serum samples, levels of NO, MDA, and TOS in
OXSALINE group were higher (but not significantly) than those
in OXL100 and OXL500 groups (p> 0.05 for all comparisons).
There was no difference in TAS and OSI levels of the groups
(p> 0.05 for all comparisons) (Table 4).
5. Discussion
Estrogen, a natural antioxidant, exhibits radical scavenger
properties 22,23 and protects vascular smooth muscle cell
Table 1 Levels of NO, MDA, TOS, TAS, and OSI in the kidney tissue samples.
LOSALINE OXL100 OXL500 OXSALINE P
NO (lmol/g protein) 51.2 ± 29.1 74.1 ± 23.4 70.4 ± 34.9 80.6 ± 17.5 0.297a,*
MDA (nmol/g protein) 2.9 (2.1–6.3) 3.6 (0.7–6.1) 2.6 (1.1–3.3) 6.1 (2.4–7.9) 0.145b,*
TAS (mmol TroloxEqv./g protein) 3.2 ± 1.6 3.2 ± 1.0 3.3 ± 1.0 4.5 ± 1.9 0.389a,*
TOS (lmol H2O2 Eqv/g protein) 6.4 ± 3.7 5.8 ± 4.8 4.6 ± 2.8 9.3 ± 3.4 0.199
a,*
OS_I 0.25 ± 0.06 0.25 ± 0.04 0.26 ± 0.03 0.25 ± 0.04 0.954
a,*
NO, TAS, TOS, and OSI values are expressed as mean ± standard deviation and MDA values as median (minimum–maximum).
a One-way ANOVA.
b Kruskal Wallis test.
* p> 0.05.
Table 2 Levels of NO, MDA, TOS, TAS, and OSI in the heart tissue samples.
LOSALINE OXL100 OXL500 OXSALINE P
NO (lmol/g protein) 56.2 ± 19.7 64.6 ± 33.1 68.3 ± 39.6 47.5 ± 36.4 0.705g,*
MDA (nmol/g protein) 3.3 ± 1.1 3.3 ± 1.6 1.7 ± 0.5a 4.6 ± 1.3a 0.004g,**
TAS (mmol TroloxEqv./g protein) 2.1 (1.6–2.4)b,c,d 2.5 (1.5–5.4)b,e,f 3.1 (1.7–4.6)a,c,e 5.6 (2.2–9.3)a,d,f 0.030h,**
TOS (lmol H2O2 Eqv/g protein) 6.5 ± 3.6 8.3 ± 3.4 7.5 ± 5.0 8.9 ± 5.6 0.804
g,*
OS_I 0.16 (0.01–0.36) 0.27 (0.21–0.28) 0.28 (0.19–0.30) 0.26 (0.19–0.29) 0.282
h,*
NO, MDA and TOS values are expressed as mean ± standard deviation and TAS and OSI values as median (minimum–maximum).
a Statistically significant differences between OXL500 and OXSALINE groups (p< 0.01).
b Statistically significant differences between OXL100 and LOSALINE groups (p< 0.001).
c Statistically significant differences between OXL500 and LOSALINE groups (p< 0.001).
d Statistically significant differences between OXSALINE and LOSALINE groups (p< 0.001).
e Statistically significant differences between OXL500 and OXL100 groups (p= 0.030).
f Statistically significant differences between OXL100 and OXSALINE groups (p< 0.001).
g One-way ANOVA.
h Kruskal Wallis test.
* p> 0.05.
** p> 0.05.
Table 3 Levels of NO, MDA, TOS, TAS, and OSI in the liver tissue samples.
LOSALINE OXL100 OXL500 OXSALINE P
NO (lmol/g protein) 50.9 ± 27.0 77.6 ± 27.0 70.1 ± 16.2 73.2 ± 35.0 0.361a,*
MDA (nmol/g protein) 2.8 ± 1.1 3.1 ± 1.4 3.4 ± 2.8 4.8 ± 2.3 0.334a,*
TAS (mmol TroloxEqv./g protein) 2.2 (1.7–3.2) 2.9 (1.6–8.7) 2.7 (1.9–3.2) 4.2 (1.9–6.0) 0.307b,*
TOS (lmol H2O2 Eqv/g protein) 9.9 (5.8–13.3) 7.8 (1.4–11.8) 4.3 (0.9–10.0) 10.0 (3.9–25.9) 0.066
b,*
OS_I 0.21 (0.01–0.24) 0.24 (0.19–0.28) 0.26 (0.22–0.29) 0.26 (0.20–0.29) 0.109
b,*
NO and MDA values are expressed as mean ± standard deviation and TAS, TOS and OSI values as median (minimum–maximum).
a One-way ANOVA.
b Kruskal Wallis test.
* p> 0.05.
58 E.P. Canbolat et al.membrane phospholipids against peroxidation.24 After meno-
pause, the level of estrogen decreases in sera. Menopause
impairs oxidative system, and causes increase in LPO and
oxidative stress.2,3
In our study, we found as expected that MDA levels of
oophorectomized groups were higher compared to LOSALINE
group, although these differences were not statistically signifi-cant level. Bednarek-Tupikowska et al. found that the level of
lipid peroxide increases after menopause and can be reduced
by Hormone Replacement therapy (HRT).2 And also in other
study, it has been determined that oxidative stress markers
(MDA, glutation) and protein’s redox level increase in the
brain, liver and plasma of oophorectomized rats and all these
processes could be prevented by HRT.5 It seems to be HRT
Table 4 Levels of NO, MDA, TOS, TAS, and OSI in the serum samples.
LOSALINE OXL100 OXL500 OXSALINE P
NO (lmol/g protein) 3.4 ± 1.1 3.1 ± 1.2 2.8 ± 1.3 4.4 ± 1.9 0.235a,*
MDA (nmol/g protein) 20.1 ± 7.4 18.8 ± 5.0 18.5 ± 3.0 23.6 ± 4.4 0.335a,*
TAS (mmol TroloxEqv./g protein) 1.4 ± 0.5 1.4 ± 0.5 1.2 ± 0.2 1.3 ± 0.3 0.876a,*
TOS (lmol H2O2 Eqv/g protein) 2.4 (2.3–4.3) 2.1 (1.3–5.9) 2.2 (1.3–3.4) 4.0 (1.5–6.1) 0.163
b,*
OS_I 0.18 ± 0.06 0.16 ± 0.03 0.19 ± 0.02 0.18 ± 0.06 0.628
a,*
NO, MDA, TAS and OSI values are expressed as mean ± standard deviation and TOS values as median (minimum–maximum).
a One-way ANOVA.
b Kruskal Wallis test.
* p> 0.05.
L-carnitine in oophorectomized rats 59might be protective oxidative stress in menopause. However,
sometimes we cannot use these drugs and we are supposed
to find other choices.
It has been shown that exogenous L-carnitine is a free-
radical scavenger and it protects cells against oxygen radi-
cals.10,11 To our knowledge, there is no study in the literature
that assessed the effects of L-carnitine on oxidant and antioxi-
dant status in sera or other tissues, particularly in menopause
or in experimental/surgical menopause.
In our study, NO, MDA, TAS, TOS and OSI levels in the
various tissue specimina and sera of surgically menopause rats
were detected. These oxidative stress markers were mostly
increased in the kidney tissue specimina of OXSALINE group
when compared with the other groups, although these differ-
ences were not significant level. Oxidative stress parameters’
levels were similar in OXL100, OXL500 and LOSALINE groups.
Contrary to our hypothesis, we could not find protective effect
of L-carnitine in kidney tissues. In the literature, there is no
study on the effects of carnitine on antioxidant system and
LPO about kidney during menopause. However, Fatouros
et al. have investigated the effects of L-carnitine on oxidative
stress response in patients with renal disease and they have
observed that L-carnitine reduces exercise-induced oxidative
stress, increases levels of antioxidants, and improves perfor-
mance in patients with end-stage renal failure.25
Furthermore when we examined liver tissue specimina, NO,
MDA, TAS, TOS and OSI levels were mostly increased in
OXSALINE group when compared with the other groups.
However these differences were not significant as in the kidney
specimina. Oxidative stress parameters’ levels were similar in L-
carnitine treated groups and the LOSALINE group. In reviewing
of the literature, it could be seen that there are no menopause-
specific liver changes. However, it was known that oxidative
stress and LPO have important roles in occurence of liver
injury. L-carnitine exhibits antioxidant effect by reducing
metabolic stress and the use of L-carnitine has recently come
into question in the treatment of many diseases such as liver
disease.25 While there is no study on menopause and the use
of L-carnitine, there are studies that investigate the effects of
carnitine on liver disease in the literature. In a study
investigating the protective effects of L-carnitine against hydro-
gen peroxide cytotoxicity in hepatocytes, it has been reported
that L-carnitine that exhibits antioxidant effects by reducing
MDA and increasing catalase (CAT) and superoxide dismu-
tase (SOD), reduces cytotoxic effect of hydrogen peroxide.26
It is accepted that menopause is an important risk factor for
cardiovascular disease. In cases of estrogen deficiency such asmenopause, deterioration in oxidative system resulted in
increasing of lipoprotein oxidation which causes cardiovascu-
lar disease.27 In this study, we found that MDA (marker of
LPO) levels in heart tissue were significantly lower in OXL500
group compared to OXSALINE and this situation supports
our hypothesis that high dose L-carnitine reduces oxidative
stress in heart tissue. Conversely, there were differences in
TAS levels between the groups. This suggests that high oxida-
tive stress may be suppressed by antioxidants which increase
reactively or distinct antioxidant mechanism. Suppression of
oxidative stress by L-carnitine may play an important role in
the heart. These results may be related to treatment duration
or dose. In the literature, carnitine and its derivative have been
subjected to numerous studies which have shown promising
results.28–32 Carnitine that exerts cardio-protective effect
against hypoxia and oxidative stress, is a specific treatment
choice.30 In experimental studies, it has been determined that
carnitine administration before or during acute ischemia
increases ATP levels, while reducing oxidative stress, improves
hemodynamic parameters, and reduces the degree of ST
segment elevation.13,28,31,32 In a rat study conducted by
Gomez-Amores et al., it has been shown that chronic L-
carnitine treatment reduces systemic oxidative stress related
to hypertension and strengthens antioxidant defense.10
According to our study, NO, MDA, TAS, TOS and OSI
levels in the sera were similar between all the groups. In paral-
lel with the literature, serum levels of NO and MDA were
higher in the OXSALINE group compared to the LOSALINE
group, and serum levels of NO, MDA and TOS were lower
in the L-carnitine treated groups compared to the OXSALINE
group, although these differences were not statistically signifi-
cant. This can be explained by the rapid uptake of exogenous
carnitine via active transport from plasma to tissues.33 Gumral
et al. have examined the effects of carnitine and selenium on
oxidative stress in blood of rat induced by 2.45-GHz electro-
magnetic radiation, and they have found that LPO levels were
higher in the radiation exposure group compared to controls
and also glutathione levels were lowest in the L-carnitine
receiving group. They have concluded that L-carnitine exhib-
ited protective effect via its free radical scavenging activity in
the blood, but no such effect has been demonstrated for
selenium.34
In accordance with our hypothesis, the level of MDA (a
LPO product) in the heart tissue was higher in OXSALINE
group when compered to the OXL500 group. We couldn’t find
similar results in other tissues and sera. These results may be
related to tissue-specific antioxidant effect of L-carnitine.
60 E.P. Canbolat et al.Moreover, Topcuoglu et al. have reported similar tissue-
specific antioxidant effect for estrojen.5 Probably, L-carnitine
can act in different ways on different tissues. In our study,
L-carnitine exhibits statistically significant reduction in MDA
levels in heart tissue in surgically menopausal rats. This effect
may be dose dependant.
In conclusion, L-carnitine 500 mg/kg/day exhibits antioxi-
dant effect in the heart by reducing oxidative stress.
L-carnitine may be an alternative for menopausal supportive
treatment, because it is naturally occurring in human body,
easy-to-obtain, easy-to-administrate, cheap and has low inci-
dence of adverse events. However, there is a need for large
scale, prospective and long-term studies that evaluate the
effects of carnitine in menopause.
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